spacer
home > epc > spring 2017 > transforming software
PUBLICATIONS
European Pharmaceutical Contractor

Transforming Software

With the wide-scale adoption of clinical technologies, focus has slowly shifted from ‘how can we leverage new software and systems in our clinical trials?’ to ‘how can we best implement this software once we’ve chosen it?’ In a highly regulated industry, with patient safety and new treatment advances at stake, the priority has historically been compliance and risk management. Now that these systems are mature and reliable, identifying new ways to make them available in a more efficient and timely manner is important. Utilising iterative design is one way to address these needs.

The Triple Constraint

Anyone who has developed software or managed projects is familiar with the triangle concept – any movement of one factor impacts the equilibrium. For example, increasing the complexity of a clinical supply tool is sure to extend time to implement and development costs. Using an iterative approach helps manage these constraints as well as scope, and maintain quality while reducing time and cost.

Innovation to Date


Quality is of paramount importance with a clinical interactive response technology (IRT) system. When patients are being treated and new drugs developed, quality cannot be compromised. This quality profile must be maintained amid increasingly complex protocol designs, shorter timeline requirements and tighter budgets.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

spacer
Steve Rawbone
spacer
spacer
spacer
Stephane Delegar
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

New awareness campaign aims to help organisations prepare for GS1


More info >>

White Papers

Orthogonal Approaches for the Analysis of Protein Sequence

Ludger Ltd

One of the most important classes of biopharmaceuticals is monoclonal antibodies. They are expressed from living cells, and are consequently subject to complex biochemical pathways. Not all of these routes are fully understood, and many are sensitive to the subtlest of environmental changes. Changes such as these can affect the final biopharmaceutical sequence, structure and post-translational modifications, not to mention any changes that may occur during further purification. This often means that the final product from one batch may be different from the last in another batch. Each batch is a complicated mix of similar molecules, and analysis of the degree of batch-to-batch variation is therefore very important to the establishment of the drug's safety for medicinal use and patient administration.
More info >>

 
Industry Events

Cell & Gene Exchange 2017

22-23 May 2017, 1300 Pennsylvania Ave NW Washington, DC 20004

The Cell & Gene Exchange brings together leaders from patient advocacy groups, industry, academia and government to network, exchange ideas and explore partnership opportunities. This partnering conference will facilitate conversations among patient groups and key stakeholders to advancing potentially curative therapies for life-threatening diseases.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement